|
I.T. Murkamilov, K.A. Aitbaev, V.V. Fomin, Zh.A. Murkamilova, F.A. Yusupov, I.O. Kudaibergenova
Homocystein and folic acid in chronic kidney disease: clinical and predictive significance
|
№3 / 2021
|
|
I.T. Murkamilov, V.V. Fomin, K.A. Aitbaev, Z.R. Rayimzhanov, N.A. Redzhapova, F.A. Yusupov, Z.A. Aydarov
Cytokine model of the development of cardiovascular complications in chronic kidney disease
|
№2 / 2017
|
|
S.E. Khoroshilov
Unresolver problem of calcium in phosphate-binding therapy of bone-mineral metabolism dis-turbances in patients with chronic kidney disease on program hemodialysis
|
№1 / 2014
|
|
L. Yu. Milovanova, Yu. S. Milovanov, L.V. Kozlovskaya
Nephro- cardioprotective role of the Klotho protein circulating form in patients with chronic kidney disease
|
№3 / 2013
|
|
V.V. Fomin
Isolated systolic hypertension: global risk factor
|
№1 / 2011
|
|
J.S. Milovanov, L.J. Milovanova, L.V. Kozlovskaya
Anaemia in chronic kidney disease: pathogenesis, prognostic sighnificance, treatment
|
№6 / 2010
|
|
M.A. Shestakova, S.A. Martynov
Anaemia correction in diabetic nephropathy: target haemoglobin values and cardiovascular complications
|
№5 / 2010
|
|
Hyperuricemia, arterial hypertension and chronic kidney disease: interconnection and management strategy
|
№4 / 2010
|
|
V.V. Fomin, M.M. Kurashov
From saralasin to sartans: history of the angiotensin II receptor blockade
|
№4 / 2009
|
|
Moisseev S.V., Fomin V.V., Saginova E.A.
The HOPE Study: putting it’s experience into clinical practice
|
№3 / 2009
|
|
N.A. Mukhin, MD., PhD., Prof; G.P. Arutyunov MD., PhD., Prof; V.V. Fomin MD., PhD. (Moscow)
Albuminuria as a marker of kidney injury and cardiovascular risk
|
№1 / 2009
|
Русский
